Aktis Oncology successfully completed its upsized initial public offering on the Nasdaq Global Select Market, generating approximately $318 million in gross proceeds. The offering comprised 17.65 million common shares, reflecting strong demand from institutional and retail investors. Proceeds are earmarked to advance the company’s clinical pipeline, fund ongoing trials in solid tumors and hematologic malignancies, and support general corporate purposes.

The company’s shares began trading under the symbol AKTS on January 9, 2026, with the offering scheduled to close on January 12, 2026, pending customary closing conditions. This rapid timeline—from pricing to expected closing—underscores Aktis Oncology’s efficient execution and readiness to access public capital markets. Listing on the Global Select Market positions the company among the highest-tier issuers and enhances its visibility with a broad investor base.

In addition to the base offering of 17.65 million shares, underwriters were granted a 30-day option to purchase up to 2.65 million additional shares to cover overallotments. This greenshoe provision provides the stability mechanism commonly sought by investors and suggests confidence in sustained demand post-listing. The full exercise of this option could boost total gross proceeds above $360 million, further bolstering Aktis Oncology’s balance sheet.